Front Page
PodcastEpisodes of The Next Leap podcast.
NewsPeople moves and university venture fund news.
Features
About
Contact
Login
Sign up

Wageningen University & Research

20 June 2025

Friday Five: DigitalCNC, Draig Therapeutics, LastingAsset, RIFT, ScopeBio

We take a look at some of the early-stage spinouts that caught our eye. This time: DigitalCNC, Draig Therapeutics, LastingAsset, RIFT, and ScopeBio.

Our Privacy Policy • Our Cookie Policy

© The Next Leap 2025

Manage Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

View preferences

{title} {title} {title}

Wageningen University & Research

Friday Five: DigitalCNC, Draig Therapeutics, LastingAsset, RIFT, ScopeBio